Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9888033 | 1.00 | PNP (1.00) | PNPMTAP | |
| SCHEMBL9888095 | 1.00 | PNP (1.00) | PNPMTAP | |
| SCHEMBL9888006 | 1.00 | PNP (1.00) | PNPMTAP | |
| SCHEMBL9888032 | 0.90 | PNP (0.82) | PNPMTAP | |
| SCHEMBL9888209 | 0.90 | PNP (0.85) | PNPMTAP | |
| SCHEMBL15315682 | 0.90 | PNP (0.85) | PNPMTAP | |
| SCHEMBL9888050 | 0.89 | PNP (0.80) | PNPMTAP | |
| SCHEMBL15315685 | 0.89 | PNP (0.80) | PNPMTAP | |
| SCHEMBL15315689 | 0.88 | PNP (0.81) | PNPMTAP | |
| SCHEMBL9888172 | 0.88 | PNP (0.81) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | PNP 1/4885MTAP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.